Auna Reports Q3 2026 Revenue Growth Amidst Regional Profitability Pressures
Auna (AUNA) reported third-quarter 2026 revenue of PEN 1,325 million, representing a 10% FX-neutral increase driven by higher surgical volumes and expanded oncology services. Despite top-line growth, Adjusted EBITDA fell 4.6% to PEN 231 million due to significant medical cost pressures in Colombia stemming from an oncology risk-sharing contract and revenue reconciliation penalties in Peru. The company saw strong operational performance in Mexico, where surgery volumes rose 12%, and improved cash flow management, resulting in a 95% increase in nine-month free cash flow. While profitability faced headwinds from specific medical costs and regulatory changes in Mexico, Auna's leverage ratio improved to 3.5x, moving closer to its medium-term target of 3.0x.

Tickers: $AUNA
Topics: Adjusted EBITDA Free Cash Flow Healthcare Services Oncology Services Revenue Growth